All News
Filter News
Found 332 articles
-
Even with its potential technical advantages, Novavax has some challenges.
-
Appili Therapeutics to Present as Part of Canada’s Top Three Pitches at Biocom’s Global Life Science Partnering Conference Today
2/24/2021
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.
-
The retooled COVID-19 vaccine promised by GlaxoSmithKline and vaccine giant Sanofi is entering Phase IIb testing, with new antigen dosages it hopes will boost the lackluster immune response seen in adults 50 and over during its last Phase I/II trial.
-
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
2/22/2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine.
-
Centessa Pharmaceuticals, based in Cambridge, Massachusetts and London, launched what it is calling a “novel asset-centric pharmaceutical company.”
-
Sagent Pharmaceuticals Announces Start of NIAID-Sponsored Study Investigating COVID-19 Treatments in Outpatients
2/12/2021
Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that Camostat mesilate (Camostat), is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial
-
Although Gamestop dominated the financial news this week, surging more than 1,600% in January, Novavax actually saw greater growth in 2020, with year-to-year gains of 2,731% that exceeded those of all the coronavirus stocks.
-
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
1/28/2021
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant Company to host investor conference call today at 4:30pm ET
-
Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
-
Pfizer, Moderna, AstraZeneca, and Johnson & Johnson all have trials of their respective vaccines underway in various age-groups.
-
One year and more than 410,000 deaths later, the United States is still firmly in the grips of the COVID-19 pandemic.
-
Biotech Showcase™ Digital Extends On-Demand Access to This Year’s Sessions, Content and Company Presentations Through March 2021
1/22/2021
In its 13th year, Biotech Showcase™ Digital welcomed more than 2,500 attendees, 850 investors, and 330 presenting companies last week in a virtual format to explore impactful trends, engage insightful personalities, learn about innovative companies, and meet motivated investors.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
-
US Department of Defense selects Pharm-Olam as CRO for Adalimumab COVID Therapeutic Trial
1/19/2021
Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial.
-
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.
-
Janet Woodcock, the longtime director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration is set to take over the top spot of the regulatory agency on an interim basis following the presidential inauguration of Joe Biden.
-
Oragenics Issues Letter to Stockholders
1/14/2021
Oragenics, Inc. (NYSE American: OGEN) today issued the following letter to stockholders from its President and Chief Executive Officer, Alan Joslyn, Ph.D.: To My Fellow Stockholders, With so much encouraging news recently around COVID-19 vaccine development, this is an excellent time to update
-
Slaoui will stay on as an adviser for one month. His resignation from the vaccine program was made at the request of the incoming Biden administration.
-
SCHOTT’s Lebanon, Pa. Facility Reaches New Record in Glass Vial Production for COVID-19 Vaccine
1/13/2021
SCHOTT continues to produce record-breaking numbers of pharmaceutical containers, including critical glass vials, as the U.S. prepares for COVID-19 vaccine distribution.
-
Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
1/12/2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of the casirivimab and imdevimab antibody cocktail for use in non-hospitalized COVID-19 patients to meet the federal government's Operation Warp Speed goals